GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

GlaxoSmithKline (NYSE: GSK  ) has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche (OTC:RHHBY)

But three other arms of the trial studying the GSK drug lapatinib, also called Tykerb, will continue. Those studies are evaluating Tykerb in some combination with Roche blockbuster drug trastuzumab, which is marketed as Herceptin.

"Patients assigned to the lapatinib-alone arm of the trial will discontinue lapatinib and discuss treatment options with their study physician," GSK said in the clinical trial update.

London-based GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, is studying Tykerb as an adjuvant therapy for patients with HER2-positive primary breast cancer, a particularly aggressive form of the disease. Adjuvant therapy is additional cancer treatment given after the primary treatment and surgery. It is given to reduce the risk that the cancer will return. While Tykerb is approved in more than 100 countries, including the United States, as a cancer treatment, it is not yet approved as an adjuvant therapy anywhere in the world.

The U.S. Food and Drug Administration approved Tykerb in 2007 to be used in combination with another Roche product, the chemotherapy drug Xeloda, to treat patients with advanced or metastatic breast cancer. Tykerb's sales have been growing and it generated more than $360 million revenue in 2010. U.S. Tykerb sales topped $154 million last year. But Tykerb has a long way to go to approach Herceptin's more than $6 billion in 2010 sales. To expand Tykerb's sales potential to blockbuster levels, GSK is studying the drug for additional treatments.

The phase 3 "ALTTO" trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) randomized patients to receive lapatinib, trastuzumab, trastuzumab followed by lapatinib or the combination of the two drugs. The study aims to find out whether a combination of the drugs works better than the Roche drug alone.

The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1551036, ~/Articles/ArticleHandler.aspx, 10/23/2016 3:59:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:02 PM
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***